Literature DB >> 8880588

Evidence to exclude SOX9 as a candidate gene for XY sex reversal without skeletal malformation.

C Kwok1, P N Goodfellow, J R Hawkins.   

Abstract

The skeletal malformation syndrome campomelic dysplasia (CMD1) is caused by mutations within the SOX9 gene or chromosomal rearrangement breakpoints outside SOX9. Approximately three quarters of cases of CMD1 in XY subjects show complete or partial sex reversal. As some mutations cause CMD1 alone and others cause CMD1 and sex reversal, it is conceivable that some mutations might cause sex reversal in the absence of CMD1. In this study, we have investigated this possibility by screening the entire coding region of SOX9 in 30 patients with a spectrum of XY sex reversal phenotypes. No mutations were identified, suggesting that SOX9 should not be considered a candidate gene for XY sex reversal without skeletal malformation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880588      PMCID: PMC1050742          DOI: 10.1136/jmg.33.9.800

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  1 in total

1.  Amyoplasia, the most common type of arthrogryposis: the potential for good outcome.

Authors:  J M Sells; K M Jaffe; J G Hall
Journal:  Pediatrics       Date:  1996-02       Impact factor: 7.124

  1 in total
  2 in total

1.  Report of fertility in a woman with a predominantly 46,XY karyotype in a family with multiple disorders of sexual development.

Authors:  Miroslav Dumic; Karen Lin-Su; Natasha I Leibel; Srecko Ciglar; Giovanna Vinci; Ruzica Lasan; Saroj Nimkarn; Jean D Wilson; Ken McElreavey; Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

2.  Testicular dysgenesis/regression without campomelic dysplasia in patients carrying missense mutations and upstream deletion of SOX9.

Authors:  Yuko Katoh-Fukui; Maki Igarashi; Keisuke Nagasaki; Reiko Horikawa; Toshiro Nagai; Takayoshi Tsuchiya; Erina Suzuki; Mami Miyado; Kenichiro Hata; Kazuhiko Nakabayashi; Keiko Hayashi; Yoichi Matsubara; Takashi Baba; Ken-Ichirou Morohashi; Arisa Igarashi; Tsutomu Ogata; Shuji Takada; Maki Fukami
Journal:  Mol Genet Genomic Med       Date:  2015-07-14       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.